Hikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average – What’s Next?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,921.22 ($24.37) and traded as high as GBX 1,944 ($24.66). Hikma Pharmaceuticals shares last traded at GBX 1,938 ($24.59), with a volume of 178,291 shares trading hands.

Analyst Ratings Changes

Separately, Berenberg Bank raised shares of Hikma Pharmaceuticals to a “buy” rating and raised their price target for the stock from GBX 2,100 ($26.64) to GBX 2,400 ($30.45) in a research note on Monday, September 2nd.

Hikma Pharmaceuticals Price Performance

The company has a 50 day moving average of GBX 1,907.09 and a 200 day moving average of GBX 1,921.22. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The stock has a market capitalization of £4.25 billion, a price-to-earnings ratio of 2,981.54, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.